To systematically assess the efficacy and safety of IL-17 inhibitors in patients with active ankylosing spondylitis.
Introduction Ankylosing spondylitis is a chronic disease, with a prevalence ranging from 9 to 30 per 10,000 persons of the adult population worldwide. 3 Ankylosing spondylitis is generally characterized by irreversible and structural damage of the sacroiliac and spinal joints, and finally, progressive spinal ankylosis due to new bone formation. 4 Clinical presentations of these patients include chronic back pain, morning stiffness and loss of spinal mobility, which primarily affect the pelvis and the lower back. 4 For the treatment of active ankylosing spondylitis, non-steroidal anti-inflammatory drugs (NSAIDs) are still the firstline recommended treatment approach in the current primary management recommendations. 2 6 On the other hand, there is no evidence that conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), such as methotrexate and sulfasalazine, have any role in the treatment of axial manifestations, although these medications may slightly improve the peripheral symptoms that coexist with axial disease. 7 For patients who do not respond to or tolerate NSAIDs, biological diseasemodifying antirheumatic drugs (bDMARDs), mainly tumour necrosis factor inhibitors (TNFis), have been recommended since the early 2000s. 2 6 However, approximately 30-40% of patients have disease that remains active after standardized treatment with NSAIDs and/or bDMARDs. 8− 10 The emergence of interleukin (IL)-17 inhibitors has changed the treatment landscape of active ankylosing spondylitis. 11 IL-17 is a pro-inflammatory cytokine that plays critical roles within a network of cytokines and is a key contributor to tissue repair on barrier surfaces, anti-infective immune responses, and the pathogenesis of various inflammatory diseases, especially Spondyloarthritis (SpA) manifestations, such as ankylosing spondylitis. 4 This activity indicates that IL-17 blockade is a potential and efficient treatment option. During the past decade, there has been an increasing interest in the use of IL-17 inhibitors (such as secukinumab, ixekizumab, and brodalumab) in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. 12 Secukinumab is a fully recombinant human immunoglobulin G (IgG)1 kappa monoclonal antibody (mAb) that directly inhibits IL-17A. It is the first approved IL-17 inhibitor for the treatment of patients with ankylosing spondylitis. 13 Increasing studies have displayed the efficacy of secukinumab in the treatment of ankylosing spondylitis after the first randomized controlled trials (RCTs) that focused on IL-17 blockade in ankylosing spondylitis. 14 Ixekizumab is another mAb specific for IL-17A that is approved for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. 15 16 Recently released results demonstrated that ixekizumab can also improve the clinical presentations of patients with ankylosing spondylitis. 17 18 Brodalumab is a human mAb that binds with high affinity to human IL-17 receptor A (IL-17RA) and can lead to a significantly efficacious therapeutic alternative for psoriasis and psoriatic arthritis. 19 20 21 However, a clinical trial in psoriasis was aborted after several cases of suicide attempts, even though the association between IL-17RA inhibitor and suicidal tendency is still not confirmed. 22 Clinical trials focusing on several other IL-17 inhibitors, including bimekizumab and netakimab, are underway to evaluate their therapeutic potential in ankylosing spondylitis. 11 To date, a comprehensive overview of different IL-17 inhibitors as an entity in ankylosing spondylitis has not been satisfactorily explained. In the present study, we therefore assessed the efficacy and safety of IL-17 inhibitors in the treatment of ankylosing spondylitis via a quantitative meta-analysis of data from the recently released RCTs.
Methods 6
A meta-analysis was accomplished following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for metaanalysis of interventional studies. 23 The authors declare that all supporting data are available within the article. This study did not require ethical approval or informed consent since all analyses were based on previously published data. The study protocol was prospectively registered on International Prospective Register of Systematic Reviews (PROSPERO) (registration ID: 157934).
Data sources and search strategy
Bibliographic databases (including Medline via PubMed, EMBASE via OVID, and Web of Science) were searched for publications from their inceptions to 8 November 2019, without language restrictions. A combination of the following keywords was used: "axial spondyloarthritis", "ankylosing spondylitis", "anti-interleukin-17", "anti-IL-17", "IL17 receptor blockade", "anti-IL17R", "secukinumab", "ixekizumab", "brodalumab", "bimekizumab" and "netakimab". The search was independently performed by two investigators (YY and ML), and discrepancies in the study selection were resolved by consensus. The search strategy is listed in online supplementary table S1. The references in the enrolled trials or meta-analyses were screened manually to find relevant original studies, and sponsored companies or study authors were contacted for additional information if ambiguity existed.
Study selection
All relevant data from the RCTs comparing the effects and safety of IL-17 inhibitors with those of a placebo in ankylosing spondylitis were potentially eligible for inclusion. Studies fulfilling the following inclusion criteria were enrolled in the meta-analysis: 1) participants recruited in individual studies had active or radiographic ankylosing spondylitis and met the modified New York criteria; 24 2) IL-17 inhibitors (including secukinumab, ixekizumab, and brodalumab) were compared to a placebo in the treatment of these patients; and 3) efficacy of IL-17 inhibitors was measured using Assessment of Spondyloarthritis International Society response criteria for 20% improvement (ASAS20) and ASAS40 after a minimum duration of 16 weeks, and adverse events after receiving IL-17 inhibitors or the placebo were also reported. Exclusion criteria included a non-randomized design, a nonplacebo comparative study, an unqualified article type (abstracts without full-text publication, case reports, and duplications with the same samples), and studies that enrolled less than 100 subjects.
Data extraction and quality assessment
The full-text article of all studies that were potentially available for inclusion was read by two independent raters (YY and ML). Discrepancies at any stage of the data extraction process were resolved upon consensus. Data were collected based on a predefined template, including researcher names (authors), publication year, number of subjects, IL-17 inhibitor type, drug regimen, and efficacy endpoint. We also extracted data on adverse events, including any adverse event, death, discontinuation due to adverse event, infection, and serious adverse event. We assessed the quality of studies suitable for metaanalysis using the modified Jadad tool for randomized clinical trials. 25 Jadad contains two questions for randomization and masking and one question assessing the description of withdrawals and dropouts. Studies with no less than 3 points are ranked as high quality.
Data synthesis and analysis
A meta-analysis was performed for three factors: efficacy evaluation of IL-17 inhibitors compared with that of a placebo by the primary outcome ASAS20 and secondary outcome ASAS40; IL-17 inhibitors efficacy assessment between TNFi-naïve patients and patients who had previous inadequate response or intolerance to an TNFi therapy (TNFi-IR); and a comparison of the safety profile between IL-17 inhibitors and the placebo. The metaanalyses were carried out using the Mantel-Haenszel method to determine the weight given to each study. A fixed-effects model was used when there was no significant heterogeneity, whereas a random-effects model was used in other cases. This produced a weighted estimate of the risk ratio (RR) with a 95% confidence interval (95% CI), considering the weight of the different samples. The heterogeneity amongst studies was examined on the basis of the Q-test (χ²) test. The heterogeneity was qualified by the I 2 statistic, ranging from 0-100%, in which high values of I² represent strong heterogeneity.
The sources of heterogeneity were explored by producing a Galbraith radial plot. The likelihood of publication bias was evaluated graphically by using sensitivity analysis. All statistical analyses were performed using RevMan statistical software version 5.3 (Nordic Cochrane Center, Copenhagen, Denmark) and Stata/MP version 13.0 (StataCorp, Texas, USA). P values lower than 0.05 were considered significant.
Results

Literature search and study characteristics
Initially, 3051 potentially relevant citations were screened, and 2648 remained after duplicates were removed. After manually searching the reference lists, our literature search finally identified five published articles including six clinical trials [26] [27] [28] [29] [30] with an overall 1733 patients (1153 patients received IL-17 inhibitors and 580 patients received a placebo) that could be used in this meta-analysis. The flowchart of the literature search is shown in figure 1 . All studies were phase III randomized, double-blind, placebo-controlled trials. Secukinumab was evaluated in 4 trials of 3 published articles [26] [27] [28] , and ixekizumab was used in two articles in the treatment of ankylosing spondylitis. 29 30 No data concerning brodalumab therapy in ankylosing spondylitis were published through the date of literature retrieval. The ASAS20/40 response rate of treatment for ankylosing spondylitis at week 16 was reported in all six trials, while the ASAS partial remission rate was described in three trials. 26 inhibitor significantly increased the primary endpoint of the ASAS20 response (RR=1.63, 95% CI 1.45 to 1.84, p<0.001). Subgroup analysis suggested similar results for both secukinumab (RR=1.64, 95% CI 1.41 to 1.89, p<0.001) and ixekizumab (RR=1.63, 95% CI 1.31 to 2.01, p<0.001). A χ² test for heterogeneity did not indicate heterogeneity amongst the included trials in synthetic analysis (I²=34%, p=0.18) and subgroup analysis for secukinumab (I²=60%, p=0.06) and ixekizumab (I²=0%, p=0.88) ( figure 2A) . The secondary endpoint of the ASAS40 response rate also had a significant increase in the IL-17 inhibitor regimen compared with that in the placebo treatment (RR=2.12, 95% CI 1.75 to 2.56, p<0.001), and the subgroup analysis revealed an increased ASAS40 response rate with secukinumab (RR= 1.97, 95% CI 1.57 to 2.47, p<0.001) and ixekizumab (RR=2.49, 95% CI 1.75 to 3.57, p<0.001). There was no heterogeneity across the included trials in pooled analysis (I²=55%, p=0.05) and subgroup analysis of ixekizumab (I²=0%, p=0.59), but an exception was found for secukinumab (I²=66%, p=0.03) ( figure 2B ). Subgroup analysis based on the exposure to TNFis indicated a trend towards a higher ASAS20 response rate in TNFi-naïve patients than in TNFi-IR patients after IL-17 inhibitor therapy (RR=1.27, 95% CI 1.06 to 1.52, p=0.01), but no trend was observed in the ASAS40 response rate (RR=1.31, 95% CI 1.00 to 1.72, p=0.05) at week 16 (online supplementary figure S1).
Heterogeneity analysis and publication bias
In the present study, since the I² values of the efficacy analysis were more than 50%, as demonstrated above, a Galbraith radial plot was produced to explore the potential sources of heterogeneity. Our results suggested that no study was the major source of heterogeneity (online supplementary figure S2) . A sensitivity analysis, by iteratively removing individual studies, was conducted to explore the impact of individual studies on the heterogeneity in this meta-analysis, and our findings suggested that there was no influence on the efficacy analysis after omitting any single-study estimates (online supplementary figure S3 ).
Safety profile of IL-17 inhibitors
The incidence of adverse events during the placebo-controlled periods was reported in all the included trials. Adverse events at week 16 were evaluated in this meta-analysis. There were no significant differences between IL-17 inhibitors and the placebo with regard to treatment-emergent adverse events (RR=1.19, 95% CI 1.00 to 1.43, p=0.06) ( figure 3A) , death (RR=0.70, 95% CI 0.14 to 3.52, p=0.86) (figure 3B), discontinuation due to adverse event (RR=1.18, 95% CI 0.62 to 2.26, p=0.62) (figure 3C), serious adverse events (including reactivation tuberculosis, bacterial sepsis, or invasive fungal infections) (RR=0.74, 95% CI 0.42 to 1.33, p=0.32) ( figure 3E ), or total adverse events (RR=1.08, 95% CI 0.97 to 1.19, p=0.15) ( figure 3F) . The most frequent adverse events reported were infectious diseases (RR=1.82, 95% CI 1.40 to 2.37, p<0.001) ( figure 3D ). The majority of infections were mild or moderate, with the most frequently reported being upper respiratory tract infections and nasopharyngitis. No discontinuation due to mild or moderate infectious diseases was reported in the included studies. A subsequent Q-test test showed that none of the single studies were homogeneous in this meta-analysis.
Discussion
To our knowledge, this study is the first meta-analysis focused on the efficacy and safety of IL-17 inhibitors over a placebo in patients with ankylosing spondylitis. Being distinct from the individual studies, this meta-analysis enables us to describe more comprehensive and accurate data by raising the persuasive power and resolution after synthesizing the outcomes of each analysis. Patients enrolled in these phase III clinical trials who received IL-17 inhibitor therapy showed, overall, significantly greater improvements in ASAS20/40 response rates than those not commencing equivalent treatment. Subgroup analysis after the division into secukinumab and ixekizumab confirmed these findings, even though the limited number of included trials require a cautious interpretation of the findings.
Concerning safety, pooled data across these clinical trials indicated that treatment with IL-17 inhibitors leads to a higher risk of curable non-fatal infection but not other severe adverse events, such as serious infection and infestation (including reactivation tuberculosis, bacterial sepsis, and invasive fungal infections) or death.
The main strength of the meta-analysis is that all the included studies were well-designed randomized, double-blind placebo-controlled trials. It provides a relatively large sample of patients with ankylosing spondylitis strictly recruited from more than 100 centres across Asia, Europe, and North and South America. Only mild heterogeneity was observed amongst the included studies. The findings of this meta-analysis of IL-17 inhibitors in ankylosing spondylitis agree with those meta-analyses examining the treatment of other rheumatic diseases. Previous meta-analyses have reported superior efficacy of secukinumab and ixekizumab over a placebo in achieving the American College of Rheumatology 20/50/70 risk ratios in the treatment of psoriatic arthritis. 31 32 A more recent network meta-analysis using RCT data recruiting 12 types of bDMARDs in psoriatic arthritis found that both secukinumab and ixekizumab are safe and efficacious treatments for active psoriatic arthritis during induction therapy, and further analysis suggested a superiority of secukinumab to ixekizumab in the American College of Rheumatology criteria of ACR20 and a 75% improvement in psoriasis area and severity index (PASI75). 33 Further systematic review and meta-analysis suggested a significant resolution of dactylitis of IL-17 inhibitors in psoriatic arthritis at week 24 versus placebo. 34 Several other studies also suggested that IL-17 inhibitors, as a group, appeared to be effective and well tolerated in plaque psoriasis and rheumatoid arthritis. 35− 37 Regarding the evaluation of IL-17 inhibitors in ankylosing spondylitis, one previous network metaanalysis compared the effectiveness of bDMARDs, including IL-17 inhibitors, for ankylosing spondylitis. 38 However, its results were unpersuasive on the evaluation of IL-17 inhibitors because only one early study 14 of secukinumab therapy with a relatively small sample size (24 participants receiving secukinumab and 6 placebo) was analysed in this meta-analysis.
According to our pooled results, the use of IL-17 inhibitors does not increase the risk of adverse events, with the exception of mild infectious diseases, compared to that with a placebo. Two deaths were reported amongst all the included patients treated with IL-17 inhibitors. One death caused by myocardial infarction in a patient subcutaneously receiving secukinumab (75 mg) in MEASURE 2, and one death due to suicide occurred after IL-17 inhibitor (ixekizumab) treatment in COAST-W. 30 This suicidal case was ultimately judged as unrelated to ixekizumab because the patient had a depression history of 1 year at study entry. 30 Apart from these cases, no suicidal ideation was reported across the included trials. There was no difference in the incidence of severe adverse events between IL-17 inhibitors (ranging from 0.7%-5.5%) and the placebo (0%-4.8%) in either the pooled results of our meta-analysis or the individual studies. The overall infection rate was not reported in MEASURE-3 and MEASURE-4, and the number of infectious diseases (including those of the ear, upper respiratory tract, and urinary tract infection and Candida infection) in patients treated with IL-17 inhibitors seemed to be more than that in those treated with a placebo, although statistical significance was not reached in these two trials. Finally, these adverse events did not induce an increased incidence of discontinuation of patients. These findings were consistent with those from studies of IL-17 inhibitors in psoriasis, psoriatic arthritis and rheumatoid arthritis. 31− 33 35 37 The current study has several unavoidable limitations. First, the correlation with treatment response rate for IL-17 inhibitors in ankylosing spondylitis might be dosagedependent. Secukinumab (150 mg or 300 mg) and ixekizumab (80 mg Q1W or Q4W) induced similar improvements in the ASAS20/40 response rate, 27− 30 while the lower dosage of secukinumab (75 mg) resulted in significant improvements in signs and symptoms only with a higher intravenous loading dose. 26 Due to the limitation of the data, however, a subgroup analysis based on different dosages was unable to be conducted.
These limitations might impair the power of our findings. Second, the short-term ASAS20 response rate achieved after secukinumab treatment was, for example, numerically different in TNFi-naïve subjects versus TNFi-IR subjects. 26 Our meta-analysis by TNFi experience also demonstrated that the overall ASAS20 response rate was statistically higher in TNFi-naïve patients than in TNFi-IR patients at week 16. In the single studies, the long-term (2-year) response rates were similar between TNFi-naïve subjects (observed ASAS20/40 data were 76.1-86.6%/56.3-65.7%) versus TNFi-IR subjects (observed ASAS20/40 data were 72.7-85.0%/40.9-68.8%, respectively). 28 39 The literature concerning the difference in the efficacy of IL-17 inhibitors according to history of TNFi treatment still remains unconfirmed. These findings should, therefore, be interpreted cautiously due to the limitation of the disclosure data.
Conclusions
The findings of this meta-analysis suggest that IL-17 inhibitors are significantly effective in improving ASAS20/40 response rates at week 16 in patients with active ankylosing spondylitis. IL-17 inhibitors seem to be associated with higher ASAS20 response rates in TNFi-naïve subjects than TNFi-IR subjects. Meanwhile, there is a higher incidence of infectious diseases attributable to IL-17 inhibitors than to placebo, with most infections being mild or moderate. IL-17 inhibitors can be considered a favourable option for patients with active ankylosing spondylitis, especially TNFi-IR subjects. There were no significant differences between IL-17 inhibitors and the placebo with regard to treatment-emergent adverse events (RR=1.19, 95% CI 1.00 to 1.43, p=0.06) ( figure 3A) , death (RR=0.70, 95% CI 0.14 to 3.52, p=0.86) ( figure   3B ), discontinuation due to adverse event (RR=1.18, 95% CI 0.62 to 2.26, p=0.62) ( figure 3C ), serious adverse events (including reactivation tuberculosis, bacterial sepsis, or invasive fungal infections) (RR=0.74, 95% CI 0.42 to 1.33, p=0.32) ( figure 3E ), or total adverse events (RR=1.08, 95% CI 0.97 to 1.19, p=0.15) ( figure 3F ). The most frequent adverse events reported were infectious diseases (RR=1.82, 95% CI 1.40 to 2.37, p<0.001) ( figure 3D ).
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